Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prognosis model for evaluating tumor immunotherapy related myocarditis based on sST2 and application thereof

An immunotherapy and myocarditis technology, applied in the field of biomedical testing, can solve the problems of disease outcome and prognosis judgment, invasive and risky biopsy scope of patients with non-immune myocarditis, and lack of routine popularization.

Pending Publication Date: 2020-10-30
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Endocardial biopsy is the gold standard for the diagnosis and evaluation of immunotherapy-related myocarditis, but due to its invasiveness, risk, and limitations in the scope of biopsy, it is still not routinely popularized
Based on the current evaluation methods, it is still impossible to accurately judge the disease outcome and prognosis of patients with immune myocarditis, which makes clinicians at a loss as to the course of follow-up myocarditis treatment and whether they can still receive anti-tumor therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prognosis model for evaluating tumor immunotherapy related myocarditis based on sST2 and application thereof
  • Prognosis model for evaluating tumor immunotherapy related myocarditis based on sST2 and application thereof
  • Prognosis model for evaluating tumor immunotherapy related myocarditis based on sST2 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0038] Obtain the sST2 level when myocarditis is diagnosed in tumor patients: it is detected by double-antibody sandwich enzyme-linked immunosorbent assay (enzymelinked immunosorbent assay, ELISA). Obtaining the cTnT level when myocarditis was diagnosed in tumor patients: using the principle of sandwich method and quantitative detection by electrochemiluminescence method. To obtain the NT-proBNP level of myocarditis in cancer patients: the principle of sandwich method was adopted, and the electrochemiluminescence method was used for quantitative detection. Reference interval Age <65 years old, 0-100pg / mL; age ≥65 years old, 0-300pg / mL. Obtain the results of echocardiography when patients with tumors are diagnosed with myocarditis: including heart size, left ventricular wall activity, valve condition, etc.

[0039] The patient visited the doctor on June 1, 2020, aged 70, female. 2020-1-8 Diagnosed with advanced squamous cell carcinoma of the lung. 2020-1-20 Start PD-1 monocl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a prognosis model for evaluating tumor immunotherapy related myocarditis based on sST2 and application thereof, and belongs to the technical field of biomedical detection. Theinvention provides a model for evaluating prognosis of tumor immunotherapy related myocarditis based on sST2. Immune myocarditis is a few but severe adverse reaction in tumor immunotherapy, and sST2is a novel heart marker and participates in the process of cardiac dysfunction caused by cardiac hypertrophy, myocardial fibrosis, ventricular remodeling and the like. The invention provides an sST2-based model for evaluating tumor immunotherapy related myocarditis prognosis, which is beneficial to providing reference information for disease prognosis of immunotherapy related myocarditis patientsso as to assist in clinically formulating a reasonable diagnosis and treatment scheme.

Description

technical field [0001] The invention relates to a prognostic model for evaluating tumor immunotherapy-related myocarditis based on sST2 and an application thereof, belonging to the technical field of biomedical detection. Background technique [0002] In recent years, the emergence of immune checkpoint inhibitors has profoundly changed the concept of tumor treatment and rewritten the conventional model of tumor treatment. Tumor immunotherapy has been approved for clinical application in my country, and the subsequent immune-related adverse reactions have also attracted the attention of clinicians. Immune myocarditis is a rare but serious adverse reaction in tumor immunotherapy, and its case fatality rate can be as high as 39.7%-46%. The clinical manifestations of patients with immune myocarditis vary greatly, the severity of the disease varies greatly, and the outcome and prognosis of the disease are also quite different. Some patients can improve spontaneously after drug ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G16H50/30G16H50/20
CPCG16H50/20G16H50/30
Inventor 葛均波程蕾蕾王妍姜惠琴林瑾仪张晨璐陈佳慧章箎吴薇李静王春晖沈毅辉张卉
Owner ZHONGSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com